Trump administration announces funding for PTSD research on ibogaineWIRED investigation examines Jensen Huang's comments on defining women's power in techWalmart launches early Black Friday promotions on select giftsMint Mobile offers $500 discount on select new phones for new customers signing up for a yearRussia and Iran criticize U.S. Caspian task force amid reports of joint sanction evasion effortsNewly elected US lawmakers pose for traditional group photo at Capitol ahead of 120th Congress openingUS existing home sales drop to lowest monthly level in yearsPro-Palestine philanthropist faces US extradition hearing in SpainLewisham Islamic Centre criticizes charity watchdog over warning on Palestine commentsSenegalese wrestlers succeed in beach wrestling at Dakar Youth OlympicsUS nonprofits file lawsuit seeking pause on advanced AI model trainingDemocrats convene in Denver to discuss party direction after midterm victoriesUS releases report on $12bn from Venezuelan oil, mineral resourcesPope Leo XIV urges Catholic Church to address clergy sexual abuseShooting near White House results in death, suspect later found dead
All fact checks
AI analysis

Fact check

“Because Upsher-Smith Laboratories, LLC., U.S. Agent for Sawai USA, Inc., timely requested that approval of the ANDA not be withdrawn, the approval is still in effect.”
UnverifiableConfidence: LOW

Reasoning

The claim concerns a specific regulatory action regarding an ANDA approval and a request by Upsher‑Smith Laboratories. Without any provided documents, databases, or statements from the FDA or involved parties, there is no basis to assess the factual status of the claim.

On confidence: No evidence was supplied to confirm or refute the claim.

Important context

Verification would require access to FDA records, correspondence from Upsher‑Smith Laboratories, or official notices about the ANDA status.

Evidence

No retrievable evidence was found; the verdict rests on the reporting itself and is marked accordingly.

Limitations

The assessment is limited to the absence of supplied evidence; no external sources were consulted.

Last verified:
Oct 6, 2026, 4:13 AM CDT
Pipeline:
2.1.0
Claim type:
Factual

Where this claim appeared

Teva Pharmaceuticals USA, Inc., et al.; Withdrawal of Approval of 15 Abbreviated New Drug Applications; Correction

Federal Register · Drug Administration, Human Services Department, Food, Health